- Home
- GMAB vs JEF Comparison
GMAB vs JEF Comparison
Compare GMAB & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- JEF
- Stock Information
- Founded
- GMAB 1999
- JEF 1968
- Country
- GMAB Denmark
- JEF United States
- Employees
- GMAB N/A
- JEF N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- JEF Investment Bankers/Brokers/Service
- Sector
- GMAB Health Care
- JEF Finance
- Exchange
- GMAB Nasdaq
- JEF Nasdaq
- Market Cap
- GMAB 15.4B
- JEF 13.2B
- IPO Year
- GMAB N/A
- JEF N/A
- Fundamental
- Price
- GMAB $28.61
- JEF $67.17
- Analyst Decision
- GMAB Buy
- JEF Buy
- Analyst Count
- GMAB 6
- JEF 4
- Target Price
- GMAB $37.60
- JEF $67.00
- AVG Volume (30 Days)
- GMAB 1.4M
- JEF 1.3M
- Earning Date
- GMAB 11-05-2025
- JEF 09-25-2025
- Dividend Yield
- GMAB N/A
- JEF 2.38%
- EPS Growth
- GMAB 77.72
- JEF 47.33
- EPS
- GMAB 21.62
- JEF 2.66
- Revenue
- GMAB $3,646,881,232.00
- JEF $6,867,621,000.00
- Revenue This Year
- GMAB $22.68
- JEF N/A
- Revenue Next Year
- GMAB $15.85
- JEF $12.52
- P/E Ratio
- GMAB $1.32
- JEF $25.28
- Revenue Growth
- GMAB 32.97
- JEF 19.44
- 52 Week Low
- GMAB $17.24
- JEF $39.28
- 52 Week High
- GMAB $28.74
- JEF $82.68
- Technical
- Relative Strength Index (RSI)
- GMAB 81.36
- JEF 69.65
- Support Level
- GMAB $27.58
- JEF $62.68
- Resistance Level
- GMAB $27.61
- JEF $65.54
- Average True Range (ATR)
- GMAB 0.37
- JEF 1.66
- MACD
- GMAB 0.26
- JEF 0.09
- Stochastic Oscillator
- GMAB 97.02
- JEF 99.62
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.